

**PEPTAXEL®**  
**Skin Biopsy and Dermoscopic Evaluation**

2025.12.04

In collaboration with

Soon-Hyo Kwon, M.D., Ph.D


Kyung Hee University Hospital at Gangdong

# Case 1

## Method

PEPTAXEL® was applied to the inner upper arm of three subjects. Skin biopsies were performed at Day 1, Day 2, and Day 3 post-treatment to assess spicule presence and tissue response.

case 1




Day 1 Post-Treatment

**Spicules are observed penetrating the full thickness of the epidermis, without epidermal spongiosis.**

**Inflammatory cell infiltration is observed around blood vessels, including eosinophils.**

case 1




Day 2 Post-Treatment

**Most spicules are  
no longer observed.**

**The degree of inflammatory  
cell infiltration around  
blood vessels is reduced.**

case 1



Day 3 Post-Treatment


**Inflammatory cell  
infiltration around blood  
vessels is still observed.**

case 1

Day 1 Post-Treatment


**The presence of spicules is  
observable under dermoscopy.**

case 1




Day 2 Post-Treatment


case 1




Day 3 Post-Treatment



D1




D2



D3

# Case 2

case 2




Day 1 Post-Treatment

**Inflammatory cell infiltration  
is observed around  
blood vessels.**

**The infiltrate consists mainly  
of lymphocytes, with  
eosinophils also observed,  
similar to Case 1.**


case 2



Day 2 Post-Treatment

Some spicules remain  
visible on day 2 for this case


case 2



Day 3 Post-Treatment

**Inflammatory cell infiltration  
is markedly reduced  
compared to Day 2.**

case 2




Day 1 Post-Treatment

case 2




Day 2 Post-Treatment


case 2




Day 3 Post-Treatment



D1




D2



D3

# Case 3

case 3



Day 1 Post-Treatment

**Inflammatory cell infiltration is observed around blood vessels and consists mainly of lymphocytes.**


**Unlike the previous two cases, eosinophil infiltration is not clearly observed.**

**Column-like structures formed by spicules are observed extending through the full thickness of the epidermis.**

case 3

Day 2 Post-Treatment


**The degree of inflammatory cell infiltration is reduced compared to Day 1.**




case 3

Day 3 Post-Treatment

**Mild inflammatory cell infiltration is observed.**




case 3



Day 1 Post-Treatment


**The presence of spicules is observable under dermoscopy.**

case 3




Day 2 Post-Treatment  
**Most spicules have detached.**


case 3




Day 2 Post-Treatment  
**Spicules are not observed.**



D1



D2



D3

# Conclusion

1. **Spicules are mostly shed within 3 days.**

Spicules are observed within the epidermis at Day 1 post-treatment. By approximately Day 3 post-treatment, most spicules are shed.

2. **Inflammatory response**

Following PEPTAXEL® treatment, inflammatory cell infiltration is observed around blood vessels. The infiltrate is predominantly composed of lymphocytes, with eosinophils observed in some subjects.

3. **Transient inflammatory response**

The inflammatory response gradually decreases over time and is reduced to a mild level by Day 3 post-treatment.

4. **Dermoscopic findings**

The presence of spicules can be confirmed by dermoscopy, appearing as bright, needle-like structures.

5. **Epidermal channels and drug delivery**

Spicules penetrated to the end of the epidermis, creating channels that support effective drug delivery. These channels naturally close as part of the skin's normal recovery process.

6. **Low risk of Granuloma and Adhesion**

Clinical observations confirmed that spicules in participants reached the epidermis–basal membrane. As long as spicules remain within the epidermis, the risk of granuloma formation is low. Continuous epidermal renewal allows most spicules to be naturally shed. Follow-up tracking of participants showed no evidence of adverse tissue reactions or discomfort.